Anixa Biosciences (ANIX) Status Update summary

Corporate strategy and financial position

• Maintains a strong balance sheet with over two years of cash runway and a clean capital structure, holding only common stock and no warrants or preferred shares.

• Operates a capital-efficient business model with low annual cash burn ($5–7 million), leveraging non-dilutive funding from partners like the Department of Defense and National Cancer Institute.

• Insiders, including management and board, have consistently purchased shares, reflecting confidence in the company’s prospects.

• Focuses on early monetization of programs through partnerships or outlicensing rather than building costly commercial infrastructure.

• Engages with top-tier research partners and conducts clinical trials at leading U.S. hospitals.

Clinical pipeline and program updates

• Two lead programs: a CART-T therapy for terminal ovarian cancer and a breast cancer vaccine, both in clinical trials and showing promising early results.

• CART-T therapy targets the follicle stimulating hormone receptor (FSHR), a unique solid tumor marker, and is delivered intraperitoneally to minimize systemic side effects.

• Early CART-T data show extended survival in terminal patients, with some living well beyond expected life expectancy; FDA has approved second dosing for responders.

• Breast cancer vaccine targets alpha-lactalbumin, aiming for both treatment and prevention; phase I shows strong immune response and safety, with phase II planned to compare vaccine plus standard of care versus standard care alone.

• Additional pipeline includes vaccines for ovarian, lung, prostate, and colon cancers, with preclinical work underway.

Upcoming milestones and partnership outlook

• Comprehensive breast cancer vaccine data expected at the San Antonio Breast Cancer Conference in December, with reports to the Department of Defense and FDA to follow.

• Ongoing rolling updates for CART-T therapy as new patients are treated and survival data matures.

• Active discussions with pharmaceutical partners for both lead programs, with potential deals anticipated as more data becomes available.

• Phase II breast cancer vaccine trial will enroll about 80 patients, aiming to generate data that could catalyze pharma interest and inform phase III design.